Table 3.

The regulation of Nrf2 by non-coding RNAs in cancer

Cancer type	Non-coding RNA	Remark	Ref
Breast cancer	miR-200a	miR-200a increases Nrf2 expression through Keap1 downregulation to induce antioxidant signalling	[193]
Breast cancer	miR-101	Nrf2 downregulation by miR-101 to induce apoptosis	[194]
Lung cancer	miR-144-3p	Nrf2 suppresses activation of miR-144-3p to induce cisplatin resistance	[195]
Esophageal cancer	miR-142-5p	Upregulation of miR-142-5p by polygalacin D downregulates Nrf2 in cancer suppression and apoptosis induction	[196]
Lung cancer	miR-1290	Upregulation of miR-1290 by COX-2 stimulates in CAF induction and enhancing cancer progression	[197]
Esophageal cancer	miR-27b-3p	miR-27b-3p downregulates Nrf2 to suppress cancer progression	[198]
Breast cancer	miR-93	miR-93 suppresses Nrf2 expression	[199]
Hepatocellular carcinoma	miR-340-5p	NRAL stimulates cisplatin resistance through miR-340-5p sponging to upregulate Nrf2	[200]
Hepatocellular carcinoma	miR-101	Apigenin increases miR-101 expression to suppress Nrf2 axis	[201]
Hepatocellular carcinoma	miR-340	miR-340 downregulates Nrf2 in suppressing cisplatin resistance	[202]
Hepatocellular carcinoma	miR-141	miR-141 stimulates Nrf2 through Keap1 suppression in drug resistance	[203]
Leukemia	miR-144-3p	miR-144-3p downregulates Nrf2 expression	[204]
Prostate cancer	LMNTD2-AS1	LMNTD2-AS1 interacts with Nrf2 through binding to FUS in increasing cancer progression	[205]
Prostate cancer	TUG1	TUG1 increases Nrf2 expression to elevate proliferation and invasion	[206]
Esophageal cancer	TUG1	TUG1 upregulates Nrf2 to induce cisplatin resistance	[207]
Colorectal cancer	LINC00239	LINC00239 increases Nrf2 stability through Keap1 inhibition for suppressing ferroptosis	[208]